Brind.

Analysis of Revvity and Codexis: Valuation, Risk, and Market Positioning

1 report, 1 independent Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

An analysis comparing Revvity and Codexis found differences in their financial profiles, including profitability, valuation, and risk. Revvity has a beta of 1.09, while Codexis has a beta of 2.52, indicating higher stock price volatility for Codexis. Analysts currently favor Codexis due to its stronger consensus rating and higher possible upside potential compared to Revvity.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The comparison of the two healthcare companies highlights differing market perceptions regarding risk and growth potential. Codexis's higher consensus rating and potential upside suggest strong investor interest, while Revvity's higher institutional ownership indicates established market backing.

From dailypolitical.com

Who's involved

  • RevvityAmerican biotech company competing for market share in the healthcare sector
  • CodexisAmerican protein engineering company competing for market share in the healthcare sector

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • RevvitySpeculative

    Revvity's stock price might be affected by its lower volatility compared to competitors, influencing investor demand.

  • CodexisSpeculative

    Codexis's higher volatility could affect its funding and investment costs due to increased market risk.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped